Market Trends of Lupus Anticoagulant Testing Industry
Dilute Russell's Viper Venom Time Test is Expected to Show Significant Growth During the Forecast Period
Dilute Russell's viper venom time (dRVVT) is a laboratory test to detect lupus anticoagulant (LA). It assesses the time for blood to clot in the presence of a diluted amount of venom from Russell's viper. The dilute Russell's viper venom time test uses Russell's viper venom (RVV) in a system containing limiting quantities of diluted rabbit brain phospholipid. The major factors driving the segment revenue are increasing dRVVT utilization compared to other lupus anticoagulant tests and growing strategic activities such as product launches by key players.
The increasing utilization of the dilute Russell's viper venom time test is expected to increase the demand for the dRVVT test, ultimately driving the segment revenue during the forecast period. For instance, according to an article published in Research and Practice in Thrombosis and Hemostasis in February 2022, dilute Russell's viper venom time is the most commonly used test for the detection of lupus anticoagulants (LA). The potent venom used in this test is highly sensitive to blood clotting factors such as factor X, factor V, prothrombin, fibrinogen, and plasminogen. Due to the high sensitivity of this test, it was utilized more in the identification of lupus anticoagulants. Hence, the increasing utilization of dilute Russell’s viper venom time test is expected to drive the market during the forecast period.
Also, key players' growing strategic activities, such as new reagent launches, are expected to drive the market during the forecast period. For instance, in January 2022, BioMedica Diagnostics, a diagnostic solutions provider, launched a DVVconfirm reagent, in conjunction with DVVtest, used to identify lupus anticoagulants. Hence, such product launches are expected to drive the market during the forecast period.
Thus, the increasing utilization of the dRVVt test and growing strategic activities such as product launches are expected to drive the segment growth during the forecast period.
North America is Expected to Hold a Significant Market Share During the Forecast Period
North America's lupus anticoagulant testing market is expected to witness a significant market share during the forecast period. This is due to the well-developed healthcare infrastructure, rising research investments in blood clotting disorders, and increasing prevalence of disorders like antiphospholipid syndrome and systemic lupus erythematosus disease.
The increasing government investments in blood clotting disorders such as lupus are expected to increase the research and development activities for the development of novel diagnosis and treatment procedures, which ultimately boost the market during the forecast period. For instance, in the United States, the National Institute of Health (NIH) invested USD 138 million in 2022 in research and development activities for the lupus disease. Hence, such investments are expected to drive the market during the forecast period.
The lupus anticoagulant tests diagnose antiphospholipid syndrome (APS) and systemic lupus erythematosus disease. Hence, the growing prevalence of antiphospholipid syndrome and systemic lupus erythematous diseases is expected to drive the market during the forecast period. For instance, according to an article published in the BMC Research Notes in January 2022, the overall unadjusted systemic lupus erythematous prevalence per 1,00,000 persons in the United States ranged from 150.1 to 252.9 annually. Hence, the significant prevalence of systemic lupus is expected to drive the market during the forecast period.
Thus, the North American regional market is expected to witness significant growth during the forecast period due to the above-mentioned factors, such as the increasing research and development investments in blood clotting disorders and the rising prevalence of systemic lupus erythematous is expected to drive the market during the forecast period.
